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John Wilson, Hannah Cullup, Rohan Lourie, Yonghua Sheng, Anna Palkova, Kristen J. Radford, Anne M. Dickinson, Alison M. Rice, Derek N.J. Hart, 
and David J. Munster
Vol. 206, No. 2, February 16, 2009. Pages 387–398.
Due to clerical error, incorrect data were displayed in the original Figure 6, panel d, resulting in the inadvertent 
duplication of data in panels a and d. The corrected figure is below.
In addition, on page 394, paragraph three, the final sentence should read, “For each of the four leukemic cell lines 
tested, cells from RA83-treated mice produced T cell–mediated lytic responses and, for two of the cell lines, these 
responses were equal to or greater than those from the cells from RAneg-treated hu-SCID mice (Fig. 6, c–f).”
Figure 6. RA83 treatment of hu-SCID mice did not impair subsequent in vitro induction of antiviral and allo antileukemic cytotoxic T cell 
effectors from cells recovered from hu-SCID mice. 10-d posttransplant hu-SCID mice treated with 125 µg RA83 (n = 19 mice; GVHD score = 0.5 
on day 9) or RAneg (n = 5 mice; GVHD score = 3.25 on day 9) were killed, cells from spleen, bone marrow, and peritoneal washings were combined, 
and human leukocytes recovered (see Materials and methods). These cells and, as a control, an equal number of freshly thawed PBMC from the 
same donor, were stimulated in vitro with irradiated autologous PBMC plus either peptide antigen or irradiated leukemic cell lines. After two rounds 
of stimulation, T cell–mediated lysis of FMP peptide-loaded T2 cells (a), U937 (c), Raji (d), Nalm6 (e), and ALL-19 (a human primary ALL passaged in 
NOD-SCID mice [reference 40]; f) leukemic cell lines was measured by 51Cr release assay. Specific killing of T2 cells loaded with peptide from the 
naive melanoma-associated antigen Mart1 was assayed after four rounds of stimulation (b). (, RA83; ,  RAneg; , freshly thawed donor PBMC). 
Dashed lines in a and b show minimal lysis of T2 cells loaded with irrelevant HIV peptide (RA83, P < 0.01 for FMP and 0.001 for Mart1 compared 
with HIV). Data are from one representative experiment of three using one HLA-A*0201+ PBMC donor.
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 Allogeneic (allo) hematopoietic stem cell trans-
plantation (HSCT) is an eff ective therapy for 
many malignant and nonmalignant hematolog-
ical and some nonhematological conditions. 
Conditioning the recipient with radiation and 
chemotherapy enables donor hematopoietic and 
immune systems to engraft and provide im-
mune eff ectors, which confer protective im-
munity and, for leukemia patients, the desired 
therapeutic graft versus leukemia (GVL) eff ect. 
Donor T cell – mediated acute graft-versus-host 
disease (GVHD), which targets recipient skin, 
gut, liver, lung, and lymphoid tissue, is an in-
evitable consequence of alloHSCT and a major 
cause of morbidity and mortality ( 1 ). GVHD 
arises within the conditioning-induced infl am-
matory milieu as donor CD4 + and CD8 + T cells 
are stimulated to generate alloreactive antihost 
eff ector cells. Mouse alloHSCT models indi-
cate that the donor antihost T cell response is 
stimulated by direct alloantigen presentation by 
host APC, particularly DC ( 2, 3 ). Donor APC 
also contribute, presumably via the indirect 
pathway by processing and presenting host an-
tigens to donor T cells ( 4 ). That they may be 
an appropriate therapeutic target in their own 
right is further supported by recent studies 
showing that donor APC propagate GVHD 
initiated by host APC ( 5 ), that they can inde-
pendently induce GVHD ( 6 ), and that they 
play a key role in HSCT rejection ( 7 ). 
 Prophylactic, and often additional therapeutic 
immunosuppression, is used to control GVHD 
but, being nonspecifi c, this neither spares preex-
isting donor memory cells nor discriminates 
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 Allogeneic (allo) hematopoietic stem cell transplantation is an effective therapy for hema-
tological malignancies but it is limited by acute graft-versus-host disease (GVHD). Den-
dritic cells (DC) play a major role in the allo T cell stimulation causing GVHD. Current 
immunosuppressive measures to control GVHD target T cells but compromise posttransplant 
immunity in the patient, particularly to cytomegalovirus (CMV) and residual malignant 
cells. We showed that treatment of allo mixed lymphocyte cultures with activated human 
DC-depleting CD83 antibody suppressed alloproliferation but preserved T cell numbers, 
including those specifi c for CMV. We also tested CD83 antibody in the human T cell –
 dependent peripheral blood mononuclear cell transplanted SCID (hu-SCID) mouse model of 
GVHD. We showed that this model requires human DC and that CD83 antibody treatment 
prevented GVHD but, unlike conventional immunosuppressants, did not prevent engraft-
ment of human T cells, including cytotoxic T lymphocytes (CTL) responsive to viruses and 
malignant cells. Immunization of CD83 antibody-treated hu-SCID mice with irradiated 
human leukemic cell lines induced allo antileukemic CTL effectors in vivo that lysed  51 Cr-
labeled leukemic target cells in vitro without further stimulation. Antibodies that target 
activated DC are a promising new therapeutic approach to the control of GVHD. 
© 2009 Wilson et al. This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the fi rst six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons
.org/licenses/by-nc-sa/3.0/).
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DC, thereby reducing DC-stimulated allo T cell proliferation 
in MLC ( Fig. 1 a ) ( 14 ). The therapeutic antibody alemtu-
zumab, which depletes most human PBMC by ADCC and 
complement-dependent cytotoxicity, also reduced T cell 
proliferation ( Fig. 1 a ) but, unlike RA83, it substantially re-
duced the total number of viable leukocytes recovered at day 
7 from the allo MLC ( Fig. 1 b ). Of the fi ve cytokines assayed 
at day 7, RA83 treatment reduced only IFN-  secretion into 
the culture medium ( Fig. 1 c ). Alemtuzumab reduced IFN-
  , IL-5, and IL-10. However, TNF and IL-4 were not af-
fected by either antibody treatment despite the large reduction 
in cell numbers induced by alemtuzumab. 
 Anti-CD83 treatment of the MLC preserves specifi c 
T cell immunity 
 The RA83-mediated reduction in T cell alloproliferation 
( Fig. 1 a ), without T cell loss ( Fig. 1 b ), suggested the hy-
pothesis that this approach to immunosuppression would not 
compromise T cell memory. To investigate this, antibody-
treated 7-d allo MLCs using CMV + HLA-A*0201 + responder 
PBMC were tested for the presence of CMV and infl uenza-
specifi c CD8 + T cells. For each of three donors, approxi-
mately similar absolute numbers of CMVpp65-specifi c CD8 + 
T cells were recovered from untreated MLCs and those 
treated with RA83 or negative control antibody (RAneg). 
Much lower numbers were recovered from alemtuzumab-
treated MLCs (0, 1.3, and 7.7% of respective RA83 values for 
the three donors;  Fig. 2 a ). The same number of total live 
cells from each MLC were stimulated with CMVpp65 pep-
tide or infl uenza matrix protein (FMP) peptide and irradiated 
autologous PBMC and then tested for specifi c cytotoxic ac-
tivity. Cells expanded from RA83, RAneg, and untreated 
MLCs all lysed CMV peptide or FMP peptide-loaded  51 Cr-
labeled T2 target cells. In contrast, alemtuzumab-treated 
MLC-derived cells lysed signifi cantly fewer target cells, indi-
cating that most CMV- and FMP-specifi c precursors in the 
MLC had been eliminated by this antibody ( Fig. 2 b ). These 
data support our hypothesis that antibody that targets acti-
vated DC could control GVHD yet maintain protective 
T cell memory. 
 Human DC are required for GVHD in the chimeric human 
PBMC-transplanted SCID mouse model (hu-SCID) 
 To test this hypothesis in vivo, we used the well established 
chimeric hu-SCID mouse model, in which human donor 
CD4 + T cells mediate GVHD in SCID mice ( 17, 18 ). In our 
hands, conditioned SCID mice injected i.p. with 50  × 10 6 hu-
man PBMC reliably developed a fatal GVHD-like syndrome 
within 8 – 13 d. Histological examination showed periportal 
lymphocytic infi ltration (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20070723/DC1), which is 
typical of GVHD in this model ( 19 ) and in patients ( 20 ). 
Mice were killed when an overall GVHD score of 5 was at-
tained, refl ecting severe GVHD, at which time human donor 
cells were detected in spleen, bone marrow, and peritoneal 
cavity (Fig. S2). 
between alloreactive and nonalloreactive donor T cells. Thus, 
although GVHD can be controlled, it is at the cost of in-
creased incidence of graft failure, leukemia relapse ( 8 ), and 
compromised immunity to posttransplant infection, partic-
ularly to CMV ( 9 ). GVHD and/or immunosuppression-
associated complications prevent the application of alloHSCT 
to older patients and limit its wider use for the treatment of 
nonhematopoietic tumors, common nonmalignant conditions 
(autoimmune disease, thalassemia, and immunodefi ciencies), 
and for gene replacement therapy ( 10 ). 
 An alternative strategy that primarily targets DC might pre-
vent GVHD without the complications associated with T cell 
immunosuppression. Depletion of APC (including DC) in mice 
with liposomal clodronate reduced development of liver GVHD 
( 11 ), and UV radiation to deplete host skin DC prevented 
mouse skin GVHD ( 12 ). More practical methods aimed at DC 
are required for clinical therapy. Antibodies can be used to target 
specifi c cells and some are available for therapeutic T cell deple-
tion and immunosuppression. However, there are no pan-DC –
 specifi c antibodies; therefore, it is not currently possible, and 
possibly not desirable, to specifi cally deplete all human DC to 
achieve immunosuppression. However, a proportion of human 
DC spontaneously up-regulate the DC surface activation mark-
ers CD83 and CMRF-44 after overnight culture ( 13 ). These 
activated DC are the prime stimulators of allo T cell prolifera-
tion in vitro and their depletion with antibody specifi c for CD83 
( 14 ) or CMRF-44 antigen ( 15, 16 ) signifi cantly reduces the allo 
proliferative response, suggesting that such antibodies may have 
a role in the control of GVHD. We show in this paper that 
treatment of MLC with anti-human CD83 antibody markedly 
reduced allo T cell proliferation but preserved preexisting anti-
viral, particularly anti-CMV eff ector/memory CD8 + T cells. In 
contrast, the therapeutic immunosuppressive antibody alemtu-
zumab (Campath-1H) prevented allo T cell proliferation by de-
pleting virtually all cells including virus-specifi c T cells. 
 To investigate the antihuman CD83 antibody in vivo, we 
used a chimeric human/mouse model of xenogeneic GVHD 
( 17 ) in which SCID mice are engrafted with human PBMC. 
These hu-SCID mice develop a fatal human CD4 + T cell – de-
pendent GVHD-like syndrome aff ecting multiple organs, which 
has histological features similar to those seen in allo human and 
mouse GVHD ( 18 ). We show in this paper that human DC 
were required to induce GVHD in this model. Treatment of 
the hu-SCID mice with CD83 antibody prevented GVHD yet 
allowed human leukocyte engraftment and preserved T cells, 
including CTL precursors specifi c for CMV, infl uenza, and the 
malignancy-associated antigen Mart1. Moreover, CD83 anti-
body treatment of hu-SCID mice did not impair in vivo induc-
tion of antileukemic cytolytic T cell eff ectors in response to 
immunization with human leukemic cell lines. 
 RESULTS 
 Anti-CD83 antibody in allo MLC reduces T cell proliferation 
and IFN-  expression but maintains cell numbers 
 Polyclonal rabbit antihuman CD83 (RA83) induces anti-
body-dependent cellular cytotoxic (ADCC) lysis of activated 
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aff ected induction of GVHD ( ≥ 80% of mice achieved a 
GVHD score of 5 within 13 d;  Fig. 3 b ). This confi rmed that 
human DC are required to stimulate the human antimouse 
CD4 + T cell eff ectors to induce GVHD and validated the 
hu-SCID model for evaluating human DC targeted therapy. 
 In vivo anti-CD83 antibody treatment prevents GVHD 
and alters circulating human cytokine concentrations 
in the hu-SCID model 
 We administered RA83 to hu-SCID mice after determining by 
ELISA that the antibody had a circulating half life of   10 d (un-
published data). RA83 administration attenuated GVHD in the 
hu-SCID model, as assessed by blinded GVHD scoring, in a 
dose-dependent manner ( Fig. 3 c ). 94% of mice injected i.p. 
with 125  μ g RA83 per mouse at the time of transplant survived 
 Mouse APC are weak stimulators of human T cells in vi-
tro ( 21, 22 ); therefore, we considered it likely that APC in 
the human donor PBMC graft provided the primary stimula-
tion of the human CD4 + T cell GVHD eff ectors in the hu-
SCID model. Supporting this view, purifi ed human T cell 
(97% CD3 + ) grafts alone induced GVHD in only 30% of 
SCID mice ( Fig. 3 a ). A high incidence of GVHD was fully 
restored by coadministration of 2.5% human autologous 
monocyte – derived DC with the purifi ed T cells ( Fig. 3 a ). 
Thus, human APC are required to induce full GVHD in the 
hu-SCID model. To explore the role of other human APC 
besides DC and of other human leukocytes, we depleted 
PBMC, before transplant, of CD14 + cells (monocytes), 
CD19 + cells (B cells), CD16 + /CD56 + cells (NK cells), and 
CD8 + cells (T cells). None of these depletions signifi cantly 
 Figure 1.  RA83 reduces T cell proliferation and expression of IFN-  in allo MLC without nonspecifi c ablation of leukocytes.  (a) Cell prolifera-
tion ([ 3 H]thymidine incorporation; CPM) was signifi cantly reduced in MLCs treated with 5  μ g/ml of RA83 or with 5  μ g/ml of alemtuzumab (Alem), com-
pared with 5  μ g/ml of RAneg (nonimmune rabbit IgG-negative control antibody). Median and interquartile range (error bars) are shown for  n = 9 
stimulator/responder combinations. (b) The number of viable leukocytes recovered from 7-d MLCs was not affected by RA83 but was substantially re-
duced by alemtuzumab. Median viable cell count and interquartile range (error bars) are shown for  n = 11 stimulator/responder combinations. (c) RA83 
reduced 7-d MLC concentrations of IFN-  (note log scale) by a median of 64%, but TNF, IL-4, IL-5, and IL-10 were not signifi cantly affected. Alemtuzumab 
similarly reduced 7-d MLC concentrations of IFN-  (median 75% reduction), IL-5, and IL-10. Graphs show, for each antibody treatment, individual cyto-
kine concentrations for  n = 6 stimulator/responder combinations, each linked by lines. Raw cytokine data contained zero values; therefore, 1.0 pg/ml was 
added to all cytokine data to enable log transformation for statistical analysis (P  > 0.05). NS and p-values are for repeated measures ANOVA followed by 
Bonferroni-corrected multiple comparisons posttests for RA83 and alemtuzumab each compared with RAneg treatment. Data are also shown for 
untreated (Nil) MLCs, which were not statistically signifi cantly different from RAneg-treated cultures. 
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for 30 d, which is in contrast to RAneg-treated control mice, all 
of which developed severe GVHD within 11 d. In the same ex-
periment, a lower dose of 25  μ g RA83 per mouse protected 
only 47% of the mice for the full 30-d experimental period. 
 Alemtuzumab also prevented GVHD in this model 
( Fig. 3 c ). From day 3 after transplant, body weights increased and 
 Figure 2.  RA83 treatment preserves virus-specifi c T cell immunity 
in allo MLC.  (a) Number of CMVpp65 pentamer-positive CD8 + T cells 
surviving after 7 d in antibody-treated 10-ml MLCs. The day 0 column 
shows the starting number of cells (data shown is for three different HLA-
A*0201 + CMV + donors; lines link data from the same donor). (b) A sub-
stantial viral antigen-specifi c functional CTL response was generated from 
7-d RA83- (  ), RAneg- (  ), and Nil (  )-treated MLCs but not from alem-
tuzumab (  )-treated MLCs. Graphs show the mean percentage of lysis of 
CMV and FMP peptide-loaded  51 Cr-labeled target cells by CTL effectors 
generated from the treated MLCs. P  < 0.0001 for CMV ( n = 3 donors) and 
P  < 0.02 for FMP ( n = 4 donors) for repeated measures ANOVA. Subse-
quent Bonferroni-corrected multiple comparisons testing showed that 
alemtuzumab treatment was signifi cantly different from each of the 
other treatments (P  < 0.001 for CMV and P  < 0.01 for FMP). 
 Figure 3.  Hu-SCID model of GVHD.  (a) Human DC enable full GVHD induc-
tion. Administration of purifi ed T cells (97% CD3 + ) alone induced severe GVHD 
in only 3 out of 10 mice (  ; not signifi cantly different from untransplanted 
controls [  ]), but coadministration of 2.5% autologous monocyte-derived DC 
(MoDC) restored the incidence of severe GVHD (six out of seven mice;   ) to 
PBMC levels (10 out of 10 mice;  	 , P  > 0.05 for MoDC + T cells vs. PBMC). P = 
0.025 for T cells only versus MoDC + T cells (combined data from two experi-
ments using two different PBMC donors). (b) Monocytes and B cells are not 
required for GVHD induction. In vitro depletion of monocytes (X), B cells (+), 
CD8 + T cells (  ), and NK cells (*) from human PBMC before administration to 
mice did not prevent or delay development of GVHD (each depletion was tested 
on  n = 5 mice and 1 PBMC donor; P  > 0.05 for each depletion vs. undepleted 
PBMC transplanted mice [ 	 ]). Administration of irradiated (3000cGy) PBMC ( 
 ) 
or of vehicle alone (untransplanted [  ]) did not induce GVHD as assessed by 
GVHD score. (c) In vivo treatment with anti-CD83 antibody prevents GVHD. i.p. 
injection of conditioned SCID mice with RA83 (125  μ g,   ; 25  μ g,   ) or alemtu-
zumab (5  μ g,   ) 3 h before PBMC administration prevented GVHD (combined 
data from three experiments using three different PBMC donors; 8 – 18 mice for 
each treatment; *, no transplant;   , nil antibody;   , 25  μ g RAneg;  
 ,125  μ g 
RAneg). P  < 0.002 for RA83 versus RAneg for 125- and 25- μ g doses. 
JEM VOL. 206, February 16, 2009 
ARTICLE
391
transplanted mice. Higher circulating human IFN-  (P = 0.01) 
and IL-5 (P  < 0.05) concentrations were observed in RA83-
treated mice at day 30 compared with alemtuzumab-treated 
GVHD scores decreased for mice treated with RA83 (125  μ g/
mouse), alemtuzumab (Fig. S3, available at http://www.jem
.org/cgi/content/full/jem.20070723/DC1), or for control un-
 Figure 4.  RA83 treatment reduces signs of GVHD in the hu-SCID model. In vivo treatment of hu-SCID mice with anti-CD83 antibody signifi cantly 
reduced GVHD score (a), weight loss (b), lymphocyte infi ltration in liver (c) and in lung (d) and circulating human IFN-  , IL-8, and IL-10 (e). RA83 (125  μ g/
mouse) was always compared with RAneg (125  μ g); alemtuzumab (5  μ g) and untransplanted (No tx) mice were always compared with Nil antibody-treated 
transplanted mice. P-values are shown only when  < 0.05. The RA83 outlier in d and the alemtuzumab outliers in e for IL-5 and IL-10 were omitted for statisti-
cal analysis. Combined data from two experiments are shown, both using the same PBMC donor.  n = 5 – 7 mice per treatment, each killed 8 – 11 d after trans-
plant when a Nil- or RAneg-treated control mouse developed severe GVHD (score  ≥ 5). Horizontal lines are median values. Symbols are the same as in Fig. 2 b. 
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 To make direct temporal comparisons between treat-
ments, each time a mouse attained a GVHD score of  ≥ 5, it was 
killed together with the highest scoring mouse from each other 
treatment group in the experiment. This occurred 8 – 13 d 
mice, indicating greater T cell engraftment of the RA83-
treated mice at this time (Fig. S4). Administration of RA83 i.
p. was as eff ective as the i.v. route (unpublished data) so i.p. 
injections were used in subsequent experiments. 
 Figure 5.  RA83 treatment did not prevent engraftment of human leukocytes (a), total CD8 + T cells (b), or CMV-specifi c CD8 + T cells (c) in 
the hu-SCID mouse model of GVHD. Dots show, for each treated hu-SCID mouse, the total number of human cells recovered from bone marrow, 
spleen and peritoneal cavity, combined, 8 – 11 d after transplant. Heavy horizontal lines show median values. Raw CMV data contained zero values; there-
fore, 1.0 was added to all CMV data to enable log transformation for statistical analysis (p-values are shown for selected posttests).  n = 5 hu-SCID mice 
per antibody treatment (one experiment using 1 CMV + HLA-A*0201 + PBMC donor). 
JEM VOL. 206, February 16, 2009 
ARTICLE
393
tuzumab (P  < 0.001 for each treatment when compared with 
6.0 [5.0 – 6.5] for 25  μ g RAneg and 5.5 [5.0 – 6.0] for 125  μ g 
of RAneg-treated controls;  n = 4 – 5 mice per treatment, 8 – 11 d 
after transplant). We also tested the therapeutic immunosup-
pressant anti-thymocyte globulin (ATG), a rabbit polyclonal 
antihuman thymocyte globulin which, like alemtuzumab, has 
broad specifi city for human leukocytes. ATG was as eff ective 
as RA83; the mean GVHD score for hu-SCID mice treated 
with 125  μ g ATG was 1.0 (0 – 2.25). 
 The numbers of live cells in spleen, femoral bone marrow, 
and peritoneal washings from each killed mouse for all treat-
ments were counted at the time that the control hu-SCID 
mice developed severe GVHD. The three samples from 
each mouse were then pooled for fl ow cytometric analysis, 
enabling calculation of absolute numbers of human CD45 + 
leukocytes, total human CD8 + T cells, and CMVpp65 pen-
tamer + CD8 + T cells recovered from each mouse. Very low 
numbers of human CD45 + leukocytes were recovered from 
hu-SCID mice treated with ATG and alemtuzumab, com-
pared with controls ( Fig. 5 a ). The median number of human 
CD45 + leukocytes recovered from RA83 (125  μ g)-treated 
mice was 147 times greater than for ATG-treated mice 
(P  < 0.001;  Fig. 5 a ), even though both antibodies protected 
mice from GVHD equally well. Recoveries of total CD8 + 
T cells and CMVpp65 pentamer + CD8 + T cells followed 
after transplant, depending on the donor. At the time that 
control hu-SCID mice were suff ering severe GVHD, un-
transplanted mice and transplanted mice treated with either 
RA83 or alemtuzumab had signifi cantly reduced GVHD 
scores ( Fig. 4 a ) and body weight loss ( Fig. 4 b ). Liver and 
lung from the RA83-treated hu-SCID mice had reduced 
GVHD-associated lymphocytic infi ltration and cell damage 
( Fig. 4, c and d ). RA83 and alemtuzumab treatments each 
substantially reduced the circulating concentrations of the 
human cytokines IFN-  , IL-8, and IL-10 (P  < 0.05) but 
maintained IL-4 ( Fig. 4 e ). TNF and IL-5 concentrations 
were also reduced by alemtuzumab treatment (P  < 0.05), but 
any reductions caused by RA83 did not reach statistical sig-
nifi cance ( Fig. 4 e ). 
 In vivo anti-CD83 antibody treatment prevents GVHD 
without ablative immunosuppression and loss of T cell 
immunity 
 To assess the eff ects of RA83 treatment on the recovery of 
CMV-specifi c human CD8 + T cells, we repeated the tempo-
ral comparison from the previous section using a CMV + 
HLA-A*0201 + PBMC donor. For this donor, 25  μ g RA83 
per mouse prevented GVHD as eff ectively as 125  μ g. Median 
GVHD scores were 0.5 (range 0.5 – 1.5) for 25  μ g RA83, 1.0 
(0.5 – 2.25) for 125  μ g RA83, and 0.5 (0 – 0.5) for 5  μ g alem-
 Figure 6.  RA83 treatment of hu-SCID mice did not impair subsequent in vitro induction of antiviral and allo antileukemic cytotoxic T cell 
effectors from cells recovered from hu-SCID mice. 10-d posttransplant hu-SCID mice treated with 125  μ g RA83 ( n = 19 mice; GVHD score = 0.5 on 
day 9) or RAneg ( n = 5 mice; GVHD score = 3.25 on day 9) were killed, cells from spleen, bone marrow, and peritoneal washings were combined, and hu-
man leukocytes recovered (see Materials and methods). These cells and, as a control, an equal number of freshly thawed PBMC from the same donor, were 
stimulated in vitro with irradiated autologous PBMC plus either peptide antigen or irradiated leukemic cell lines. After two rounds of stimulation, T cell –
 mediated lysis of FMP peptide-loaded T2 cells (a), U937 (c), Raji (d), Nalm6 (e), and ALL-19 (a human primary ALL passaged in NOD-SCID mice [reference 
 40 ]; f) leukemic cell lines was measured by  51 Cr release assay. Specifi c killing of T2 cells loaded with peptide from the naive melanoma-associated antigen 
Mart1 was assayed after four rounds of stimulation (b). (  , RA83;   , RAneg;   , freshly thawed donor PBMC). Dashed lines in a and b show minimal lysis 
of T2 cells loaded with irrelevant HIV peptide (RA83, P  < 0.01 for FMP and 0.001 for Mart1 compared with HIV). Data are from one representative experi-
ment of three using one HLA-A*0201 + PBMC donor. 
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 Our in vitro comparison of the polyclonal anti-CD83 an-
tibody (RA83) with the CD52 mAb alemtuzumab provided 
insight into their mechanisms of immunosuppression. Both 
antibodies reduced allo T cell proliferation and expression of 
the TH1 cytokine IFN-  , but alemtuzumab also reduced the 
TH2 cytokine IL-5 and the immunosuppressive cytokine IL-
10, presumably as a result of its pan-leukocyte – depleting ca-
pacity. RA83 had little direct eff ect on T cells, as it did not 
signifi cantly reduce the number of viable mononuclear cells 
recovered from the allo MLC ( Fig. 1 b ), nor did it destroy pre-
existing CMV-specifi c nor fl u-specifi c CD8 + T cells ( Fig. 2 ). 
 Alloproliferating CD4 + T cell blasts, which were generated 
during MLC and found in the highest numbers after 96 h, 
similar trends ( Fig. 5, b and c ; and Fig. S5, available at 
http://www.jem.org/cgi/content/full/jem.20070723/DC1). 
Notably, the median number of CMVpp65 pentamer + 
CD8 + T cells recovered from each RA83 (125  μ g)-treated 
mouse was 255, compared with zero for alemtuzumab treated 
mice (P  < 0.05). 
 To further assess the eff ect of RA83 treatment on reten-
tion of immunity we harvested cells from RA83- and RAneg-
treated hu-SCID mice transplanted with PBMC from a 
diff erent HLA-A*0201 + donor. Human cells were isolated 
(see Materials and methods) and stimulated with irradiated 
autologous PBMC loaded with HLA-A*0201 + peptides from 
FMP and from the model tumor antigen Mart1. This in-
duced expansion of FMP and Mart1 pentamer + CTL (not 
depicted), which specifi cally lysed FMP and Mart1 peptide-
loaded T2 cells, respectively, regardless of RA83 or RAneg 
treatment of the hu-SCID mice from which the precursor 
cells were recovered ( Fig. 6, a and b ). 
 We assessed the potential for GVL by also stimulating in 
vitro the cells recovered from the RA83- and RAneg-treated 
hu-SCID mice in the experiment described in the previous 
paragraph with irradiated autologous PBMC and irradiated 
allo human leukemic cell lines. For three of the four leuke-
mic cell lines tested, cells from RA83 treated mice produced 
T cell – mediated lytic responses equal to or greater than the 
cells from RAneg-treated hu-SCID mice ( Fig. 6, c – f ). 
 The eff ect of RA83 treatment on the induction of GVL 
in vivo was investigated in two separate experiments using 
diff erent PBMC donors. RA83- and RAneg-treated hu-
SCID mice were immunized on days 0 and 7 after transplant 
with irradiated U937 or Raji cells (10 7 cells i.p.). All hu-
SCID mice were killed on day 9 or 10 (donor dependent), 
when the GVHD clinical score for RAneg-treated mice was 
signifi cantly greater than for RA83 treated mice (P  ≤ 0.001). 
Human cells recovered from the mice (see Materials and 
methods) were used as eff ectors, without further stimula-
tion, in a chromium release assay with  51 Cr-labeled U937 or 
Raji cells as targets. Human cells recovered from nonimmu-
nized hu-SCID control mice were poor lytic eff ectors 
against U937 or Raji targets, whereas cells from immunized 
hu-SCID mice lysed the appropriate targets, regardless of 
the previous RA83 or RAneg antibody treatment of the 
mice ( Fig. 7 ). 
 DISCUSSION 
 We show in this paper that antibody specifi c for the DC acti-
vation marker CD83 is a potential new therapeutic option 
for the control of GVHD in alloHSCT. Our in vitro and in 
vivo evidence shows that CD83 antibody not only limits the 
uncontrolled T cell proliferative response that characterizes 
GVHD but preserves the donor T cell repertoire, in particu-
lar, potentially life saving antiviral memory T cells and anti-
leukemic eff ectors. Current GVHD prophylaxis, be it ex vivo 
T cell depletion of the graft before transplant or nonspecifi c 
immunosuppression, does not spare these vital components 
of the donor graft ( 23 ). 
 Figure 7.  RA83 treatment did not impair in vivo induction of 
human allo antileukemic cytotoxic T cell effectors as a result of 
immunization of hu-SCID mice with irradiated leukemic cell lines. 
RA83- or RAneg-treated hu-SCID mice were immunized by i.p. injection 
on days 0 and 7 with 10 7 irradiated (3000cGy) U937 cells (a), Raji cells (b), 
or vehicle alone. All mice were killed on days 10 – 11, and cells from perito-
neal cavity, spleen, and bone marrow were combined within each cohort. 
After removal of dead cells, erythrocytes and mouse CD45 + cells, the re-
maining cells ( > 95% human CD45 + ), were tested for cytotoxic activity, 
without further stimulation, in a  51 Cr release assay using U937 (a) or Raji 
(b) cells as targets. Effectors were from immunized mice (solid lines) 
treated with RA83 (  ) or with RAneg (  ) or from negative controls (dot-
ted lines;   , freshly thawed donor PBMC;   , nonimmunized RAneg-
treated hu-SCID mice). Data are from two experiments using two 
different PBMC donors. Error bars show technical reproducibility (1SEM) 
and are each calculated from fi ve replicate wells. 
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suppressants that target T cells, exemplifi ed here by alem-
tuzumab and ATG, compromise posttransplant immunity, 
particularly to CMV ( 35 ) and other infectious agents. 
 T cell depletion also compromises the GVL eff ect and 
predisposes to recurrence of leukemia ( 8, 36 ). Theoretically, 
specifi c depletion of activated DC to control GVHD in clini-
cal alloHSCT should preserve the antileukemia T cell reper-
toire. Supporting this, from cells recovered from RA83 treated 
hu-SCID mice, we obtained human eff ector T cell responses 
to the naive tumor-associated antigen Mart1 ( Fig. 6 b ) and to 
allo human leukemic cell lines, particularly to U937 (AML; 
 Fig. 6 c ) and Raji (B cell lymphoma;  Fig. 6 d ) cells. 
 A potential disadvantage of targeting CD83 + DC for the 
prevention of GVHD in alloHSCT patients is that these DC 
may be required for the induction of GVL eff ectors from an-
tileukemic precursors, be they T or NK cells. Reddy et al 
( 37 ) showed in a mouse  “ acute leukemia ” model that host 
and, to a lesser extent, donor DC are required for eff ective 
GVL after alloHSCT, although the role of DC activation was 
not explored. Encouragingly, we found that RA83 did not 
prevent in vitro induction of allo cytotoxic antileukemic cell 
line activity by cocultured PBMC (Fig. S6, available at 
http://www.jem.org/cgi/content/full/jem.20070723/DC1). 
Furthermore, RA83 treatment of hu-SCID mice immu-
nized with the human leukemic cell lines U937 and Raji 
did not impair in vivo induction of antileukemic cytotoxic 
T cell eff ectors ( Fig.7 ). Nevertheless, if GVL proves to be 
compromised by peritransplant DC-targeted treatment, it 
could be managed by subsequent vaccination with leukemia 
antigen-loaded donor DC or by donor leukocyte infusions, 
perhaps boosted by donor vaccination before transplantation. 
Alternatively, to retain peritransplant antileukemia priming 
by host CD83 + DC, antibody treatment might await the ap-
pearance, after transplant, of activated DC in the circulation, 
an event which precedes clinical GVHD ( 38 ). 
 Any signifi cant improvement in the control of GVHD as 
a result of targeting DC may allow wider utilization of al-
loHSCT for malignant conditions and for nonmalignant 
conditions, which do not require GVL. Our data provides 
compelling evidence that depletion of activated human DC is 
a promising alternative GVHD prevention strategy that war-
rants further investigation. A DC targeted therapy, which 
prevents alloreactive GVHD-inducing T cell generation, even 
allowing immature DC-mediated tolerance induction, which 
nonetheless, still preserves protective and therapeutic T cells, 
would also have wider applications in allotransplantation. 
 MATERIALS AND METHODS 
 Antibodies.  Rabbit polyclonal IgG anti – human CD83 (RA83) was pre-
pared as described previously ( 14, 39 ) but with an added CD83 antigen af-
fi nity purifi cation step (see Supplementary Materials and methods [available 
at http://www.jem.org/cgi/content/full/jem.20070723/DC1] for prepara-
tion and validation). Clinical grade ATG (Fresenius) and alemtuzumab 
(Schering) were obtained from the Mater Health Services Pharmacy. 
 Human PBMC and cell preparations.  PBMC were obtained with in-
formed consent from normal healthy donors either as whole blood donations 
or by leukapheresis (approved by the Mater Human Research Ethics 
express low levels of CD83 and are also susceptible targets of 
RA83-mediated ADCC lysis ( 14 ) but to a lesser extent than 
activated CD83 + DC (4.4-fold less lysis at 10:1 E/T ratio 
[calculated from data in reference  14 ]). Delayed addition of 
RA83 to the MLC reduced its inhibitory eff ect on alloprolif-
eration, completely negating its eff ect, when administered af-
ter 96 h to target the alloresponding T cells ( 14 ). Thus, the 
functional cellular target of RA83 is present early rather than 
late during the course of MLC, which is consistent with the 
principal target being the DC. 
 To obtain in vivo evidence for immunosuppressive effi  -
cacy of CD83 antibody, we chose a chimeric human/mouse 
model of GVHD because antibodies specifi c for human CD83 
and CD52 antigens, such as RA83 and alemtuzumab, can be 
tested. The SCID mouse was used in preference to other 
immunodefi cient strains, despite the requirement for higher 
donor cell doses ( 24 ), because the hu-SCID model of GVHD has 
been used more extensively than others ( 25 ), it is complement 
replete ( 26 ), and functional human NK cells are present ( 27 ), 
allowing for antibody-mediated complement-dependent cyto-
toxicity and ADCC lysis of human target cells in vivo. The 
hu-SCID model of GVHD requires human CD4 + T cells ( 17 ), 
but the stimulatory cells had not previously been identifi ed and 
mouse APC are known to be weak stimulators of human 
T cells ( 21, 22, 28, 29 ). We therefore considered it likely that 
human DC in the graft would play a major role, and this was 
supported by fi nding that purifi ed human T cells required sup-
plementation with human DC to be fully eff ective at inducing 
GVHD in conditioned SCID mice ( Fig. 3 a ). 
 Using the hu-SCID model, we found that RA83 prevented 
GVHD ( Fig. 3 c ). RA83-treated mice had signifi cantly lower 
GVHD scores and less weight loss than RAneg-treated or un-
treated controls when the latter had severe GVHD ( Fig. 4, a and 
b ). Circulating levels of human IFN-  and IL-8 were substan-
tially reduced in RA83-treated mice but not IL-4 ( Fig. 4 e ), 
which is consistent with a GVHD-ameliorative TH2 cytokine 
milieu predicted by the in vitro studies ( Fig. 1 c ). RA83 treat-
ment is expected to leave potentially tolerogenic nonactivated 
(CD83    ) DC intact, and these may induce regulatory T cells 
( 30 ) with potential allosuppressive benefi ts. RA83 may also se-
lectively retain TH2 inducing plasmacytoid DC ( 31 ), as they 
express comparatively low levels of CD83 when activated ( 13 ). 
 Alemtuzumab treatment also prevented GVHD in the 
hu-SCID model but at the expense of T cell engraftment, 
particularly CMV-specifi c CD8 + T cells ( Fig. 5 c ). In marked 
contrast, RA83 treatment prevented GVHD without the loss 
of specifi c donor T cell immune memory. Treating trans-
plant patients with CD83 antibody at the time of condition-
ing should limit the generation of a large pool of alloreactive 
GVHD inducing eff ector/memory T cells immediately after 
transplantation, which, at least in an allo mouse model, can 
induce GVHD at any time subsequently in the absence of 
host DC ( 32 – 34 ). Antibody that targets activated DC, such as 
that studied here, should also preserve donor T cell immunity 
to common infections such as CMV, which cause major 
posttransplant mortality and morbidity. Current immuno-
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cavity, femoral bone marrow, and spleen were treated with red cell ACK 
lysis buff er and live cells counted by Trypan blue exclusion. PBMC and 
cells from mice were stained with fl uorophore-conjugated antibodies 
(human CD3 clone SK7, CD8 SK1, CD45 2D1, and mouse CD45 30-F11 
[BD]). Flow cytometry data were analyzed using FCS Express software. 
In some experiments, cells harvested from hu-SCID mice, as in the pre-
vious section, were combined and human leukocytes recovered by den-
sity gradient centrifugation (Ficoll Hypaque) and depletion with mouse 
CD45 immunomagnetic beads (Miltenyi Biotec), for subsequent in vitro 
CTL experiments. 
 Mouse tissues were fi xed in 10% formalin, paraffi  n embedded, sec-
tioned, and stained with hematoxylin and eosin. The degree of lymphocytic 
infi ltration was assessed by examination of one to two entire full face sec-
tions. Liver was scored between 0 (nil lymphocytes) and 2.5 (moderate infi l-
tration), to which 1.0 was added for any focal apoptosis and hepatitis. Lung 
was scored between 0 and 3.5 for degree of perivascular lymphocytic infi ltra-
tion, and 1.0 was added for any peribronchiolar infi ltration. 
 Statistical analysis.  We used GraphPad Prism 4.0 (GraphPad Software, 
Inc.) and SYSTAT 10.2 (SYSTAT Software, Inc). Survival data were ana-
lyzed using the Kaplan-Meier log-rank test, with Bonferroni corrected 
posttest multiple comparisons. All other data (log transformed where clearly 
non-Gaussian and indicated in fi gure legends) were analyzed by ANOVA 
(repeated measures where indicated in legends) and, if statistically signif-
icant (P  < 0.05), Bonferroni-corrected multiple comparisons posttests 
were done. 
 Online supplemental material.  Fig. S1 shows histology of liver from a 
hu-SCID mouse with GVHD and Fig. S2 shows human leukocyte engraft-
ment of hu-SCID mouse spleen, bone marrow, and peritoneal cavity by 
fl ow cytometric staining. Fig. S3 shows weight change and GVHD scores for 
antibody-treated and control hu-SCID mice, whereas Fig. S4 shows human 
leukocyte engraftment 30 d after transplant in hu-SCID mice treated with 
RA83. Fig. S5 shows human CMV-specifi c CD8 + T cells from a RA83-
treated hu-SCID mouse. Fig. S6 shows the eff ect of RA83 on in vitro in-
duction of antileukemic cell line cytotoxicity. Supplementary Materials and 
methods, with Figs. S7 – S10 embedded, describes the preparation and valida-
tion of the RA83 antibody. Online supplemental material is available at 
http://www.jem.org/cgi/content/full/jem.20070723/DC1. 
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